颅内肿瘤的靶向药物治疗  

Targeted Drug Therapy for Intracranial Tumors

作　　者：王瀚 王跃龙[1] 刘志勇[1] 徐建国[1] WANG Han;WANG Yue-long;LIU Zhi-yong;XU Jian-guo(Department of Neurosurgery,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Neurosurgery,the Second People's Hospital of Yibin,West China Hospital,Sichuan University,Yibin 644000,China)

机构地区：[1]四川大学华西医院神经外科,成都610041 [2]宜宾市第二人民医院·四川大学华西医院宜宾医院神经外科,宜宾644000

出　　处：《四川大学学报（医学版）》2022年第4期564-572,共9页Journal of Sichuan University(Medical Sciences)

基　　金：四川大学华西医院学科卓越发展1·3·5工程项目(No.ZYJC18007)资助。

摘　　要：颅内肿瘤严重影响了人类的身心健康,由于肿瘤的性质与生长部位的不同,因此对颅内肿瘤患者进行个体化、特异性的治疗已成为当下研究的热点,而颅内肿瘤的靶向药物治疗作为精准医学的重要分支,更是成为了科学家重点攻坚的对象。目前分子生物学及基因组学的迅速发展,为肿瘤的精准治疗提供了相应的靶点。但是由于血脑屏障、血肿瘤屏障阻碍了药物到达颅内靶点,因此如何提升颅内药物浓度成为了目前靶向治疗颅内肿瘤的关键所在。本文总结了不同颅内肿瘤的靶向药物治疗的现状,探讨了对于不同颅内肿瘤靶向药物治疗的效果,以期为未来靶向药物对颅内肿瘤的治疗提供新的思考。Intracranial tumors seriously affect the physical and mental health of humans.Due to variations in the nature and the growth site of tumors,individualized and specific treatment of patients with intracranial tumor has become a hotspot topic of research,and targeted drug therapy of intracranial tumors,an important subspecialty of precision medicine,has become a key issue that scientists are working hard to tackle.At present,the rapid development in molecular biology and genomics has provided corresponding targets for precision therapies of tumors.However,the blood-brain barrier and blood-tumor barrier prevent drugs from reaching intracranial targets.Therefore,finding effective ways to elevate the concentration of intracranial drugs has become the key issue concerning existing targeted therapies for intracranial tumors.Herein,we reviewed the current status of targeted drug therapy for different intracranial tumors and discussed their efficacy,intending to provide new perspectives for the treatment of intracranial tumors with targeted drugs in the future.

关 键 词：胶质瘤 脑膜瘤 垂体瘤 神经鞘瘤 颅咽管瘤 靶向药物治疗 

分 类 号：R739.41[医药卫生—肿瘤]